Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunity

ABSTRACT: Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunity

PROVIDER: PRJNA948416 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23958200.fastq.gz	Fastqsanger.gz
	SRR23958201.fastq.gz	Fastqsanger.gz
	SRR23958202.fastq.gz	Fastqsanger.gz
	SRR23958203.fastq.gz	Fastqsanger.gz
	SRR23958204.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 23

Similar Datasets

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunity

Project description:Nuclear receptors (NRs) are implicated in the regulation of tumors and immune cells. We identify a tumor-intrinsic function of the orphan NR, NR2F6, regulating anti-tumor immunity. NR2F6 was selected from 48 candidate NRs, based on an expression pattern in melanoma patient specimens (i.e., IFN signature) associated with positive responses to immunotherapy and favorable patient outcomes. Correspondingly, genetic ablation of NR2F6 in a mouse melanoma model conferred a more effective response to PD-1 therapy. NR2F6 loss in B16F10 and YUMM1.7 melanoma cells attenuated tumor development in immune-competent but not -incompetent mice via the increased abundance of effector and progenitor-exhausted CD8+ T cells. Inhibition of NACC1 and FKBP10, identified as NR2F6 effectors, phenocopied NR2F6 loss. Remarkably, inoculation of NR2F6 KO mice with NR2F6 KD melanoma cells further decreased tumor growth compared with NR2F6 WT mice. Tumor-intrinsic NR2F6 function complements its tumor-extrinsic role and justifies the development of novel anti-cancer therapies.

2023-09-11 | GSE228162 | GEO

The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity [RNA-seq]

Project description:The regulation of proper gene transcription is critical for anti-viral defense. Dynamics of enhancer activity play important roles in many biological processes, and epigenomic analysis is widely used to determine the involved enhancers and transcription factors. To determine new transcription factors in anti-DNA-virus response, we perform H3K27ac ChIP-Seq analysis to profile the active enhancer pattern in HSV-1-infected THP-1 cells. We have identified three transcription factors, NR2F6, MEF2D and MAFF, and experimentally verified their roles in promoting HSV-1 replication. NR2F6 promotes HSV-1 replication and gene expression in vitro and in vivo, which is not related with the classical cGAS/STING pathway. NR2F6 binds to the promoter of MAP3K5 and activate AP-1/c-Jun pathway, which is critical for DNA virus replication. On the contrary, NR2F6 expression is transcriptionally repressed by c-Jun upon HSV-1 infection, which forms a negative feedback loop. Meanwhile, cGAS/STING innate immunity signaling represses NR2F6 through STAT3. Taken together, we have identified new transcription factors involved in the interactive network between DNA viruses and host cells, and revealed the underlying mechanisms for anti-viral research.

2024-05-30 | GSE249664 | GEO

The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity [ChIP-seq]

2024-05-30 | GSE249663 | GEO

The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity

Project description:The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity

| PRJNA1050145 | ENA

The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity [ChIP-seq]

Project description:The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity [ChIP-seq]

| PRJNA1050147 | ENA

The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity [RNA-seq]

Project description:The roles of nuclear orphan receptor NR2F6 in anti-viral innate immunity [RNA-seq]

| PRJNA1050148 | ENA

Nuclear Receptor NR2F6 as an Alternative Cancer Immune Checkpoint in the T Cell Compartment

Project description:Analyzing mouse tumor models in vivo, human T cells ex vivo and human lung cancer samples, we provide direct evidence that NR2F6 acts as novel immune checkpoint. Genetic ablation of Nr2f6, particularly in combination with blockade of the established PD-L1 cancer immune checkpoint, efficiently delayed tumor progression and improved survival in experimental mouse models. The target genes deregulated in intratumoral T lymphocytes upon genetic ablation of Nr2f6 alone or together with PD-L1 blockade, revealed multiple advantageous transcriptional alterations for effective tumor rejection. In keeping with the above observation, acute Nr2f6 silencing in both mouse and human T cells induced hyper-responsiveness that established a non-redundant T cell-inhibitory function of NR2F6. Analyzing mouse tumor models in vivo, human T cells ex vivo and human lung cancer samples,

2018-03-14 | GSE111796 | GEO

Effect of Nr2f6 knockdown in C2C12 myocytes

Project description:Investigate the transcriptional landscape changes promoted by Nr2f6 knockdown in C2C12 myocytes. We performed RNA-seq analysis in control non-target (siScr) and siNr2f6 transfected myocytes.

2024-04-05 | GSE229102 | GEO

Fucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: Fucose Click Chemistry

Project description:Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient stratification, efficacy is impaired by paucity of intratumoral immune cells (itICs)—thus, effective strategies to safely increase itICs are needed. We report that dietary administration of L-fucose induces fucosylation and cell surface enrichment of the MHC-II protein HLA-DRB1 in melanoma cells, triggering CD4+T cell-mediated increases in ItICs and anti-tumor immunity, enhancing immune checkpoint blockade responses. Melanoma fucosylation and fucosylated HLA-DRB1 associate with intratumoral T cell abundance and anti-PD1 responder status in patient melanoma specimens, suggesting the potential use of melanoma fucosylation as a strategy for stratifying patients for immunotherapies. Our findings demonstrate that fucosylation is a key mediator of anti-tumor immunity, and importantly, suggest that L-fucose is a powerful agent for safely increasing ItICs and immunotherapy efficacy in melanoma.

2022-12-16 | PXD038303 | Pride

Fucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: HLA-DRB1 Interactomes

2022-12-16 | PXD038068 | Pride